New hepatitis C treatment very effective: Over 90 percent success rate in patients with cirrhosis

April 15, 2014 12:01 AM

21 0

AbbVie's experimental hepatitis C drug that cured over 90 percent of the subjects in its phase 3 trial is set to compete with Gilead's Sovaldi once it gets FDA's approval. Researchers conducting the phase 3 trial of the drug called ABT-450, reported that the experimental drug has cured more than 90 percent of the subjects who have hepatitis C and liver cirrhosis.

(Photo : Steven Depolo)

Read more

To category page